SLC22A8 is expressed only in HepG2 cells compared to normal liver cells.[13] In contrast, increased protein expression of SLC22A8 in acute lymphoblastic leukemia cells and its mediated clearance of furosemide may in turn lead to an increased risk of clinical treatment failure and drug resistance.[14] However, few studies have been conducted to elucidate how SLC22A8 is involved in the biological process of renal clear cell carcinoma. Here, SLC22A8 is linked to acute lymphoblastic leukemia.